IQVIA and Veeva Systems have expanded their partnership. IQVIA Veeva clinical operations now includes Veeva CTMS, eTMF, Study Startup and Site Connect as enterprise standard applications across IQVIA clinical development studies, extending the earlier EDC partnership.
IQVIA Life Science Models were introduced at TechIQ 2026 to help life sciences companies predict clinical trial outcomes. IQVIA reports that 85% of predictions across 50 trials and 270 endpoints were on target or clinically close.
IQVIA has launched IQVIA Predictive Clinical Development, an AI-powered platform built with Anthropic, AWS, Databricks, Microsoft, NVIDIA, Palantir and Snowflake, designed to help sponsors bring new therapies to market up to two years faster.
IQVIA’s AI-enabled Clinical Decision Support Tool, built with Breakthrough T1D, won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year after cutting T1D misdiagnosis screening workload by 99.5% and lifting diagnostic yield 127-fold.
IQVIA Q2 2026 results show revenue up 8.7% to $4.368 billion, Adjusted EPS of $3.15, and a raised full-year 2026 outlook, driven by record R&D Solutions bookings and accelerating Commercial Solutions growth.
IQVIA Holdings Inc. announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. The acquisition includes five sites specializing in in vitro drug discovery services, supported by over 20 years of scientific data, creating an industry-leading integrated drug discovery platform.
Following the release of its IQVIA 2025 earnings, the life sciences leader reported a record-breaking $32.7 billion backlog and a double-digit revenue surge in the fourth quarter, outperforming Wall Street expectations. As the company transitions into 2026, it is doubling down on a specialized Healthcare-grade AI strategy—anchored by its proprietary Med-R1 reasoning model and strategic cloud partnerships with NVIDIA and AWS—to safeguard its core business against industry-wide disruption.
For the third quarter that concluded on September 30, 2025, IQVIA Holdings Inc. (NYSE: IQV) posted solid financial results. The company’s profit and revenue were [Read More…]
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
